About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immunic, Inc. (Exact name of registrant as specified in its charter) | Delaware | | 56-2358443 | | --- | --- | --- | | (State or ot ...

– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update – Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million – – Net Proceeds Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis and Begin of Trans ...

– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – – Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million – – Net Proceeds Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis and Begin of Transition into a Commercial Organization – NEW YORK, Feb. 26, 2026 Â /PRNewswire/ --Â Im ...

Immunic Therapeutics Developing Selective Oral Therapies in Immunology NASDAQ: IMUX | February 2026 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management's intentions, plans, beliefs, e ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Core Viewpoint - Immunic, Inc. has successfully closed an oversubscribed private placement financing, raising an upfront total of USD 200 million, with the potential for an additional USD 200 million, aimed at funding clinical trials and transitioning into a commercial organization [1] Financing Details - The financing was led by BVF Partners L.P. and included participation from various institutional investors [1] - Immunic issued 229,076,000 pre-funded warrants at a price of USD 0.873 per warrant, resulting in upfront gross proceeds of USD 200 million [1] - Additional warrants for the purchase of up to 229,076,000 shares at the same exercise price could generate up to another USD 200 million [1] Use of Proceeds - The net proceeds from the offering will be utilized to fund clinical trials, operations, and general corporate purposes [1] - The combined funds from this private placement and existing cash reserves are expected to support operations into late 2027 [1] Clinical Development Programs - Immunic's lead program, vidofludimus calcium (IMU-838), is in Phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [1] - The company is also initiating a Phase 3 trial for primary progressive multiple sclerosis [1] - Other development programs include IMU-856, targeting gastrointestinal diseases, and IMU-381, currently in preclinical testing [1]

Core Insights - Immunic Inc presented new data from the CALIPER Phase 2 trial at the ACTRIMS Forum, focusing on progressive multiple sclerosis (MS) and highlighting the efficacy of Vidofludimus calcium in reducing both acute and chronic inflammation [1][2][3] Group 1: CALIPER Trial Findings - The CALIPER trial showed a statistically significant reduction in slowly expanding lesions (SELs) for the 45mg dose of Vidofludimus calcium compared to placebo, indicating potential efficacy on chronic inflammation [7] - Vidofludimus calcium demonstrated a reducing effect on gadolinium-enhancing and T2 lesions, suggesting its impact on acute inflammation in MS [5] Group 2: EBV Reactivation Study - The trial provided clinical evidence of reduced Epstein-Barr virus (EBV) reactivation compared to placebo, which is significant given the role of EBV in MS progression [9] - T-cell receptor repertoire analysis indicated that under treatment with Vidofludimus calcium, EBV antigens dropped in ranking, suggesting fewer reactivations [10] Group 3: Future Outlook - Immunic is preparing for the readout of Phase 3 trials in relapsing MS, with results expected at the end of 2026 from two identical trials enrolling over 1,100 patients each, totaling more than 3,000 individuals [12]

Core Viewpoint - Immunic Inc (NASDAQ:IMUX) is experiencing a significant stock surge following the announcement of a private placement of up to $400 million, indicating strong investor confidence and potential for future growth [1]. Group 1: Financing Details - The financing round was led by existing investor BVF Partners, with participation from notable institutional investors including OrbiMed, RA Capital, Janus Henderson, Avidity Partners, and EcoR1 Capital [2]. - The structure of the deal includes $200 million upfront through pre-funded warrants priced at 87 cents each, with an additional potential $200 million contingent on the exercise of accompanying warrants [3]. Group 2: Use of Funds - The new capital is expected to sustain Immunic through late 2027, primarily funding the completion of Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis, with top-line data anticipated by the end of 2026 [4]. - If the Phase 3 ENSURE trial results are positive, the company plans to file for regulatory approval in mid-2027, targeting a potential green light in 2028 [4]. - Additionally, the financing will enable Immunic to initiate a Phase 3 program in primary progressive multiple sclerosis (PPMS) later this year, with the study projected to last approximately three and a half to four years [5]. Group 3: Stock Performance - Following the announcement, Immunic shares rose by 26.43%, reaching a price of $1.10 at the time of publication [5].

Company Overview - Proactive is a provider of fast, accessible, informative, and actionable business and finance news content aimed at a global investment audience [2] - The company operates with a team of experienced and qualified news journalists across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain quality and best practices in content production [5]